Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick^™ dry-powder inhaler in the treatment of asthma

References

• Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA) 2015; [cited 2016 Mar 4]. Available from: http://www.ginasthma.org
   Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Immunology and Allergy. Chest. 2005;127:335–371.
   PubMed Web of Science ®Google Scholar
• Teva Respiratory LLC ProAir RespiClick Prescribing Information; [updated 2016 Apr; cited 2016 Jun 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205636s004lbl.pdf
   Google Scholar
• Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2013;26:239–248.
   PubMed Web of Science ®Google Scholar
• Amphastar Pharmaceuticals Ltd. Albuterol DPI (A006) clinical study-B2: efficacy, dose-ranging and initial safety evaluation. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2000−2016 Mar 23]. NLM Identifier: NCT01581177. Available from: https://clinicaltrials.gov/ct2/show/NCT01581177
   Google Scholar
• Amphastar Pharmaceuticals Ltd. Albuterol DPI (A006) clinical study-B3: efficacy, dose-ranging and safety evaluation. ClinicalTrials.gov identifier [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2000−2016 Mar 10]. NLM Identifier: NCT02210806. Available from: https://clinicaltrials.gov/ct2/show/NCT02210806.
   Google Scholar
• IVAX Laboratories, Inc. ProAir HFA Prescribing Information; [updated 2005 Oct; cited 2016 Mar 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021457s002,004lbl.pdf
   Google Scholar
• Merck Sharp & Dohme Corp. Proventil Prescribing Information; [updated 2014 Dec; cited 2016 Mar 10]. Available from: https://www.merck.com/product/usa/pi_circulars/p/proventil_hfa/proventil_hfa_pi.pdf
   Google Scholar
• GlaxoSmithKline. Ventolin HFA Prescribing Information; [updated 2014 Dec; cited 2016 Mar 10]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ventolin_HFA/pdf/VENTOLIN-HFA-PI-PIL.PDF
   Google Scholar
• Sunovion Pharmaceuticals Inc. Xopenex Prescribing Information; 2015 [cited 2016 Mar 10]. Available from: http://www.respistory.com/aa/ast/XOPENEX-HFA-Prescribing-Information.pdf
   Google Scholar
• GlaxoSmithKline UK. Ventolin Accuhaler Summary of Product Characteristics; [updated 2015 Jul 9; cited 2016 Mar 10]. Available from: https://www.medicines.org.uk/emc/medicine/97
   Google Scholar
• GlaxoSmithKline UK. Ventolin Easyhaler Summary of Product Characteristics; [updated 2015 Jul 9; cited 2016 Mar 10]. Available from: https://www.medicines.org.uk/emc/medicine/21084
   Google Scholar
• The Inhaler Error Steering Committee, Price D, Bosnic-Antisevich S, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Resp Med. 2013;107:37–46.
   PubMed Web of Science ®Google Scholar
• Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000;94:496–500.
   PubMed Web of Science ®Google Scholar
• Levy ML, Hardwell A, McKnight E, et al. Asthma patients’ inability to use a pressurised metered-dose inhaler (pMDI) correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013;22:406–411.
   PubMedGoogle Scholar
• Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma. 2008;45:109–113.
   PubMed Web of Science ®Google Scholar
• Westerik JA, Carter V, Chrystyn H, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. J Asthma. 2016;53:321–329.
   PubMed Web of Science ®Google Scholar
• Capanoglu M, Misirlioglu ED, Toyran M, et al. Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers. J Asthma. 2015;52:838–845.
   PubMed Web of Science ®Google Scholar
• Sleath B, Ayala GX, Gillette C, et al. Provider demonstration and assessment of child device technique during pediatric asthma visits. Pediatrics. 2011;127:642–648.
   PubMed Web of Science ®Google Scholar
• Melani AS, Danchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Asthma Allergy Immunol. 2004;93:439–446.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–254.
   PubMedGoogle Scholar
• Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasibility and acceptability of training by pharmacists. Resp Med. 2011;105:1815–1822.
   PubMed Web of Science ®Google Scholar
• Giraud V, Allaert FA. Improved asthma control with breath-actuated pressurized metered dose inhaler (pMDI): the SYSTER survey. Eur Rev Med Pharmacol Sci. 2009;13:323–330.
   PubMed Web of Science ®Google Scholar
• Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003;97:181–187.
   PubMed Web of Science ®Google Scholar
• Borgström I. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med. 2001;14:281–287.
   PubMedGoogle Scholar
• Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28:202–212.
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Badiola C, et al. Patient perception and acceptability of multidose dry-powder inhalers: a randomised crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med. 2002;15:59–64.
   PubMedGoogle Scholar
• Storms WW, Tringale M, Ferro TJ. The impact of expired and empty quick-relief asthma inhalers: the Asthma and Allergy Foundation of America’s Asthma Inhaler Design Survey. Allergy Asthma Proc. 2015;36:300–305.
   PubMed Web of Science ®Google Scholar
• Papi A, Haughney JA, Virchow JC, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Resp J. 2011;37:982–985.
   PubMed Web of Science ®Google Scholar
• Bondesson E, Friberg K, Soliman S, et al. Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. Resp Med. 1998;92:325–330.
   PubMed Web of Science ®Google Scholar
• Ramsdell JW, Klinger AM, Ekholm BP, et al. Safety of long-term treatment with HFA albuterol. Chest. 1999;115:945–951.
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and Ventolin have similar safety profiles during regular use. Chest. 1998;113:290–296.
   PubMed Web of Science ®Google Scholar
• Teva Pharma BV DuoResp® Spiromax® Summary of Product Characteristics; [updated 2015 Sep 17; cited 2016 Mar 9]. Available from: https://www.medicines.org.uk/emc/medicine/29187
   Google Scholar
• Azouz W, Chetcuti P, Hosker H, et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm Med. 2015;15:47.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Resp Med. 2003;2:287–297.
   PubMedGoogle Scholar
• Kerwin EM, Taveras H, Iverson H, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of albuterol (salbuterol) multidose dry-powder inhaler and ProAir hydrofluoroalkane for the treatment of persistent asthma: results of two randomized double-blind studies. Clin Drug Investig. 2016;36:55–66.
   PubMed Web of Science ®Google Scholar
• Teva Branded Pharmaceutical Products, R&D Inc. A 12-week study to compare the efficacy and safety of albuterol Spiromax versus a placebo in people 12 years and older with persistent asthma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2000−2016 Feb 26]. NLM Identifier: NCT01424813. Available from: https://clinicaltrials.gov/ct2/show/NCT01424813.
   Google Scholar
• Teva Branded Pharmaceutical Products, R&D Inc. Efficacy of inhaled albuterol Spiromax in subjects with persistent asthma with steady state pharmacokinetics. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2000−2016 Feb 26]. NLM Identifier: NCT01747629. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01747629.
   Google Scholar
• Raphael G, Taveras H, Iverson H, et al. Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. J Asthma. 2016;53:187–193.
   PubMed Web of Science ®Google Scholar
• Teva Branded Pharmaceutical Products, R&D Inc. Safety study of albuterol Spiromax in subjects with asthma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2000−2016 Feb 26]. NLM Identifier: NCT01698320. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01698320.
   Google Scholar
• Raphael G, Taveras H, Iverson H, et al. Efficacy of albuterol multidose dry powder inhaler versus placebo in subjects 12 years of age and older with persistent asthma. The American College of Allergy, Asthma & Immunology Annual Scientific Meeting, 2014 Nov 6–10; Atlanta, Georgia; Abstract No. 74.
   Google Scholar
• Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest. 1998;113:283–289.
   PubMed Web of Science ®Google Scholar
• Given J, Taveras H, Iverson H. Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Allergy Asthma Proc. 2016;37:1–8.
   PubMed Web of Science ®Google Scholar
• Price DA, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4:184–191.
   PubMed Web of Science ®Google Scholar
• Armour C, Bosnic-Antecevich S, Brillant M, et al. Pharmacy Asthma Care Program (CPAP) improves outcomes for patients in the community. Thorax. 2007;62:496–502.
   PubMed Web of Science ®Google Scholar
• Rootmensen GN, Van Keimpema AR, Jansen HM, et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23:323–328.
   PubMed Web of Science ®Google Scholar